GLP-1 'girl dinner' chili: what semaglutide actually does to appetite

What did @janakinskywalker1 actually say?

She said antidepressants prescribed during a major depressive episode caused significant weight gain, reversing 75 pounds of previous weight loss. She's now using a GLP-1 medication as a tool alongside calorie deficit eating, with protein sources like ground turkey, eggs, cottage cheese, and beans. She described her experience candidly: "a lot of anti-depressants do have side effects that cause weight gain." She's not claiming a cure, not selling anything, just explaining why she felt she needed pharmacological help this time around. That framing matters. She also pushed back on the idea that people owe anyone an explanation for their weight loss method, which is, frankly, a reasonable position.

The video is a cooking segment layered with personal disclosure about bipolar disorder, medication-induced weight gain, and the emotional weight of managing both mental health and body image simultaneously. It's worth fact-checking not because she made bold scientific claims, but because millions of people are in exactly this situation and deserve accurate context.

Does the science back this up?

Yes, substantially. Psychiatric medication-induced weight gain is one of the most documented and undertreated problems in metabolic health. She's describing something real, not an excuse.

Atypical antipsychotics and many mood stabilizers used in bipolar disorder, including olanzapine, quetiapine, and valproate, are among the most obesogenic medications in clinical use. A 2018 meta-analysis by Bak et al. in Acta Psychiatrica Scandinavica found that patients on second-generation antipsychotics gained an average of 3-5 kg within the first 12 weeks of treatment, with some gaining significantly more over longer periods. The mechanisms include increased appetite via histamine H1 and serotonin receptor antagonism, along with insulin resistance effects.

The GLP-1 angle is also supported. A 2022 trial published in The New England Journal of Medicine (Wilding et al., extended follow-up) confirmed semaglutide produced meaningful weight loss in people with obesity regardless of the original cause of weight gain. There is no study specifically powered on psychiatric medication-induced obesity and GLP-1 response, but the biological plausibility is solid.

What did they get wrong (or right)?

She got the core claim right, and deserves credit for that. Medication-induced weight gain is not a personal failure, and psychiatrists regularly face a painful trade-off between mental stability and metabolic consequences. Her framing, "although it might have saved my life, it actually hindered my weight loss success," reflects exactly the kind of trade-off clinicians discuss in the literature.

Where things get slightly fuzzy: she says she doesn't "want to be on it forever" and frames GLP-1 as a temporary tool. That's emotionally understandable but clinically worth interrogating. Data from the STEP 1 trial (Wilding et al., 2021, NEJM) showed that participants who stopped semaglutide regained two-thirds of lost weight within a year. GLP-1 medications are increasingly understood as chronic condition management tools, not short courses. Her goal of using it temporarily is valid as a personal preference, but she and anyone in a similar situation should have that conversation explicitly with their prescriber.

Her protein strategy, specifically leaning on eggs, beans, cottage cheese, and ground turkey while in a calorie deficit, is genuinely sound. Higher protein intake during weight loss preserves lean mass, which matters especially when GLP-1 medications suppress appetite broadly.

What should you actually know?

If you're managing bipolar disorder and experiencing medication-related weight gain, you are not imagining it and you are not uniquely weak-willed. This is a documented pharmacological effect. But here's what the video doesn't address, not as a criticism of her, but as context you need.

• Not all psychiatric medications carry equal metabolic risk. Medications like lamotrigine and aripiprazole have more favorable weight profiles than olanzapine or quetiapine. If weight gain is severe, a conversation with your psychiatrist about formulation or adjunct options is clinically legitimate, but never stop or adjust psychiatric medication without medical supervision.
• GLP-1 medications interact with gastric motility, which can affect the absorption of oral medications including some mood stabilizers. This is not widely discussed in patient-facing content but is documented in pharmacokinetic literature. Tell your prescribing provider about every medication you're on.
• The protein focus she describes is backed by evidence. Research by Leidy et al. (2015, American Journal of Clinical Nutrition) showed higher protein intake during calorie restriction preserved lean mass and improved satiety. Cottage cheese and beans are underrated high-protein, high-satiety foods.
• Calorie deficit alone while on appetite-suppressing GLP-1 medication requires monitoring. Eating too little is a real risk when hunger cues are blunted, and inadequate protein specifically accelerates muscle loss.